Clinical Efficacy of Inhaled Nitric Oxide in Preventing the Progression of Moderate to Severe COVID-19 and Its Correlation to Viral Clearance: Results of a Pilot Study
Authors:
Open Access
- 28 December 2021
- journal article
- research article
- Published by Wolters Kluwer Health in Infectious Microbes and Diseases
- Vol. 4 (1) , 26-33
Abstract
Hypoxic patients with coronavirus disease 2019 (COVID-19) are at high risk of adverse outcomes. Inhaled nitric oxide (iNO) has shown anti-viral and immunomodulatory effects in vitro. However, in vivo evidence of efficacy in hypoxic COVID-19 is sparse. This open label feasibility study was conducted at a single referral center in South India and evaluated the effectiveness of repurposed iNO in improving clinical outcomes in COVID-19 and its correlation with viral clearance. We recruited hypoxemic COVID-19 patients and allocated them into treatment (iNO) and control groups (1:1). Viral clearance on day 5 favored the treatment group (100% vs 72%, P < 0.01). The speed of viral clearance as adjudged by normalized longitudinal cycle threshold (Ct) values was positively impacted in the treatment group. The proportion of patients who attained clinical improvement, defined as a ≥2-point change on the World Health Organization ordinal scale, was higher in the iNO cohort (n = 11, 79%) as compared to the control group (n = 4, 36%) (odds ratio 6.42, 95% confidence interval 1.09-37.73, P = 0.032). The proportion of patients progressing to mechanical ventilation in the control group (4/11) was significantly higher than in the treatment group (0/14). The all-cause 28-day mortality was significantly different among the study arms, with 36% (4/11) of the patients dying in the control group while none died in the treatment group. The numbers needed to treat to prevent an additional poor outcome of death was estimated to be 2.8. Our study demonstrates the putative role of repurposed iNO in hypoxemic COVID-19 patients and calls for extended validation.Keywords
All Related Versions
This publication has 24 references indexed in Scilit:
- Inhaled NO and COVID‐19British Journal of Pharmacology, 2020
- Viral RNA load as determined by cell culture as a management tool for discharge of SARS-CoV-2 patients from infectious disease wardsEuropean Journal of Clinical Microbiology & Infectious Diseases, 2020
- Dual effect of nitric oxide on SARS-CoV replication: Viral RNA production and palmitoylation of the S protein are affectedVirology, 2009
- Inhaled Nitric Oxide Therapy in AdultsNew England Journal of Medicine, 2005
- Nitric Oxide Inhibits the Replication Cycle of Severe Acute Respiratory Syndrome CoronavirusJournal of Virology, 2005
- Inhalation of Nitric Oxide in the Treatment of Severe Acute Respiratory Syndrome: A Rescue Trial in BeijingClinical Infectious Diseases, 2004
- ALVEOLAR NEUTROPHIL OXIDATIVE BURST AND β2 INTEGRINShock, 1998
- NO Inhibitions: Antimicrobial Properties of Nitric OxideClinical Infectious Diseases, 1995
- Nitric Oxide Reverses Acute Hypoxic Pulmonary Hypertension in the Newborn PigletPediatric Research, 1994
- Interdependence of pharmacologically-induced and endothelium-mediated coronary vasodilation in antianginal therapyCardiovascular Drugs and Therapy, 1988